文献速递临床试验与 GCP流行病学与生物统计

维生素B12补充对尼泊尔婴儿神经发育和生长的影响:一项随机对照试验

Effects of vitamin B12 supplementation on neurodevelopment and growth in Nepalese Infants: A randomized controlled trial.
PubMed 文献 · PLoS Med · 2020-12-01

该研究在尼泊尔巴克塔普尔中低收入社区招募600名6-11月龄轻度发育迟缓婴儿,随机分为每日2μg维生素B12组或安慰剂组补充12个月,两组均给予约1RDA的15种其他维生素和矿物质。结果显示干预对神经发育、生长和血红蛋白浓度均无显著影响,但安慰剂组总同型半胱氨酸和甲基丙二酸浓度分别高出23%和30%。

要点

  • 每日2μg维生素B12补充12个月未改善婴儿神经发育、生长或血红蛋白浓度。
  • 补充维生素B12可改善代谢反应,安慰剂组tHcy和MMA浓度显著更高。
  • 结果不支持在低收入国家边缘化婴儿中广泛补充维生素B12。

核心结论

  • 在维生素B12缺乏风险高的幼儿中,补充维生素B12改善了代谢反应,但未影响神经发育、生长或血红蛋白浓度。
  • 结果不支持在低收入国家边缘化婴儿中广泛补充维生素B12。

研究设计与样本

  • 社区为基础的个体随机双盲安慰剂对照试验,在尼泊尔巴克塔普尔中低收入社区进行。
  • 2015年4月至2017年2月纳入600名6-11月龄轻度发育迟缓婴儿,按1:1随机分为每日2μg维生素B12组或安慰剂组,补充12个月。
  • 两组均同时给予约1RDA的15种其他维生素和矿物质。

主要发现

  • 干预对Bayley-III评分、生长和血红蛋白浓度均无显著影响。
  • 两组儿童平均生长12.5 cm(SD: 1.8),平均差异0.20 cm(95%CI: -0.23至0.63,P=0.354)。
  • 研究结束时血红蛋白浓度平均差异0.02 g/dL(95%CI: -1.33至1.37,P=0.978),认知量表分差异0.16(95%CI: -0.54至0.87,P=0.648)。
  • 安慰剂组tHcy和MMA浓度分别比维生素B12组高23%(95%CI: 17至30,P<0.001)和30%(95%CI: 15至46,P<0.001)。
  • 36名儿童发生43起不良事件,与干预无关;维生素B12组20名、安慰剂组16名儿童在补充期间住院。

临床怎么用

  • 对于低收入国家边缘化婴儿,不应常规广泛补充维生素B12以改善神经发育、生长或血红蛋白。
  • 补充维生素B12可改善代谢指标,但需结合临床背景评估其必要性。

局限性

  • 严格的纳入标准可能限制外部有效性。
  • 维生素B12补充期可能未覆盖婴儿生长或大脑发育的关键窗口。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vitamin B12 deficiency is common and affects cell division and differentiation, erythropoiesis, and the central nervous system. Several observational studies have demonstrated associations between biomarkers of vitamin B12 status with growth, neurodevelopment, and anemia. The objective of this study was to measure the effects of daily supplementation of vitamin B12 for 1 year on neurodevelopment, growth, and hemoglobin concentration in infants at risk of deficiency. METHODS AND FINDINGS: This is a community-based, individually randomized, double-blind placebo-controlled trial conducted in low- to middle-income neighborhoods in Bhaktapur, Nepal. We enrolled 600 marginally stunted, 6- to 11-month-old infants between April 2015 and February 2017. Children were randomized in a 1:1 ratio to 2 μg of vitamin B12, corresponding to approximately 2 to 3 recommended daily allowances (RDAs) or a placebo daily for 12 months. Both groups were also given 15 other vitamins and minerals at around 1 RDA. The primary outcomes were neurodevelopment measured by the Bayley Scales of Infant and Toddler Development 3rd ed. (Bayley-III), attained growth, and hemoglobin concentration. Secondary outcomes included the metabolic response measured by plasma total homocysteine (tHcy) and methylmalonic acid (MMA). A total of 16 children (2.7%) in the vitamin B12 group and 10 children (1.7%) in the placebo group were lost to follow-up. Of note, 94% of the scheduled daily doses of vitamin B12 or placebo were reported to have been consumed (in part or completely). In this study, we observed that there were no effects of the intervention on the Bayley-III scores, growth, or hemoglobin concentration. Children in both groups grew on an average 12.5 cm (SD: 1.8), and the mean difference was 0.20 cm (95% confidence interval (CI): -0.23 to 0.63, P = 0.354). Furthermore, at the end of the study, the mean difference in hemoglobin concentration was 0.02 g/dL (95% CI: -1.33 to 1.37, P = 0.978), and the difference in the cognitive scaled scores was 0.16 (95% CI: -0.54 to 0.87, P = 0.648). The tHcy and MMA concentrations were 23% (95% CI: 17 to 30, P < 0.001) and 30% (95% CI: 15 to 46, P < 0.001) higher in the placebo group than in the vitamin B12 group, respectively. We observed 43 adverse events in 36 children, and these events were not associated with the intervention. In addition, 20 in the vitamin B12 group and 16 in the placebo group were hospitalized during the supplementation period. Important limitations of the study are that the strict inclusion criteria could limit the external validity and that the period of vitamin B12 supplementation might not have covered a critical window for infant growth or brain development. CONCLUSIONS: In this study, we observed that vitamin B12 supplementation in young children at risk of vitamin B12 deficiency resulted in an improved metabolic response but did not affect neurodevelopment, growth, or hemoglobin concentration. Our results do not support widespread vitamin B12 supplementation in marginalized infants from low-income countries. TRIAL REGISTRATION: ClinicalTrials.gov NCT02272842 Universal Trial Number: U1111-1161-5187 (September 8, 2014) Trial Protocol: Original trial protocol: PMID: 28431557 (reference [18]; study protocols and plan of analysis included as Supporting information).

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Strand TA, Ulak M, Hysing M, et al. Effects of vitamin B12 supplementation on neurodevelopment and growth in Nepalese Infants: A randomized controlled trial. PLoS Med. 2020. PMID: 33259482. doi:10.1371/journal.pmed.1003430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。